Clinical trials: Extensive-Stage Small Cell Lung Cancer
Lung Cancer
Amrubicin and Irinotecan in Treating Patients With Recurrent or Relapsed Extensive Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as amrubicin and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00132054
- Testing
- amrubicin hydrochloride, irinotecan hydrochloride
- Where
- 7 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Japan Multinational Trial Organization
Small-cell Lung Cancer
Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC
This single-arm, Phase II, multicenter study was designed to evaluate the safety and efficacy of Camrelizumab (anti-programmed death-receptor 1 [PD-1] antibody) in combination with Apatinib+carboplatin plus (+) etoposide in…
- Trial name
- NCT04683198
- Testing
- camrelizumab, Apatinib Mesylate, Carboplatin
- Volunteers
- 69 people
- Sponsor
- Chinese Academy of Medical Sciences
Carcinoma, Small Cell
IMFINZI Study in Patients With Extensive Stage Small Cell Lung Cancer
To capture safety(FN) when IMF is administered to patients with extensive stage small cell lung cancer in clinical practice after launch
- Trial name
- NCT04854590
- Where
- 18 sites in Japan
- Volunteers
- 248 people
- Sponsor
- AstraZeneca
Small Cell Lung Carcinoma, Extensive Disease
Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer
The purpose of this study is to determine if a cisplatin-etoposide regimen improves survival in comparison to a regimen containing etoposide and without platinum derivative.
- Trial name
- NCT00658580
- Testing
- Cisplatin + etoposide, Epirubicin + ifosfamide + etoposide
- Where
- 4 sites in Belgium, France and 2 more
- Volunteers
- 361 people
- Sponsor
- European Lung Cancer Working Party
Small Cell Lung Cancer Extensive Stage
Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer
Current therapies for Recurrent or Extensive-Stage Small Cell Lung Cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of…
- Trial name
- NCT00003496
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Burzynski Research Institute
Extensive Stage Small Cell Lung Cancer
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC.
- Trial name
- NCT05468489
- Testing
- Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide)
- Where
- 67 sites in United States
- Volunteers
- 200 people
- Sponsor
- Shanghai Henlius Biotech
Small Cell Lung Cancer Extensive Stage
PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer
This is a prospective, single-arm clinical study designed to evaluate the 6-month progression-free survival rate (6-month PFS rate) of a PD-L1 inhibitor combined with apatinib as first-line maintenance treatment for…
- Trial name
- NCT06429696
- Testing
- PD-L1 inhibitor combined with apatinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Extensive Stage Small Cell Lung Carcinoma
Tumor-Treating Fields Therapy in Preventing Brain Tumors in Participants With Extensive-Stage Small Cell Lung Cancer
This trial studies how well tumor-treating fields therapy works in preventing brain tumors in participants with small cell lung cancer that has spread to other places in the body.
- Trial name
- NCT03607682
- Testing
- Tumor Treating Fields (TTF) Therapy, NovoTTF-200A Device, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Lung Cancer, Small Cell
A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC
This is an open-label, single-arm, prospective phase 2 study, evaluating the efficacy and safety of tislelizumab combined with sitravatinib as maintenance therapy following tislelizumab and chemotherapy for treatment naïve…
- Trial name
- NCT05228496
- Testing
- Tislelizumab, Sitravatinib
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Zhejiang Cancer Hospital
Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
This phase II trial studies the effects of temozolomide and atezolizumab as second or third line treatment for patients with small cell lung cancer that has spread to other places in the body (metastatic) or has come back…
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT04919382
- Testing
- Atezolizumab, Temozolomide
- Where
- 5 sites in United States
- Volunteers
- 56 people
- Sponsor
- Dwight Owen
Extensive-stage Small-cell Lung Cancer
Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer
This is an open label, phase 2 clinical study to evaluate the safety, tolerability, efficacy, pharmacokinetic (PK) profile, and immunogenicity of QL1706 plus carboplatin and etoposide as first-line therapy in patients with…
- Trial name
- NCT05309629
- Testing
- QL1706, Carboplatin, Etoposide
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative…
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Estrogen Receptor-negative Breast Cancer, Extensive Stage Small Cell Lung Cancer
- Trial name
- NCT00031681
- Testing
- 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Extensive Stage Small Cell Lung Carcinoma, Recurrent Small Cell Lung Carcinoma
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage
This randomized phase II trial studies cisplatin and etoposide to see how well they work when given with or without Hedgehog inhibitor GDC-0449 (vismodegib) or IGF-1R MOAB IMC-A12 (cixutumumab) in treating patients with…
- Trial name
- NCT00887159
- Testing
- Cisplatin, Cixutumumab, Etoposide
- Where
- 301 sites in United States
- Volunteers
- 168 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Breast Cancer
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Conditions
- Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer
- Trial name
- NCT00014456
- Testing
- filgrastim, docetaxel, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Small Cell Lung Cancer
Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy
This is a pilot study of patients who previously received platinum chemotherapy with recurrent SCLC to evaluate the change in the ratio of intratumoral Teff/Treg cells and clinical benefit of treatment with nivolumab and…
- Trial name
- NCT03670056
- Testing
- Combination immunotherapy with Ipilimumab and Nivolumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Yale University
Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer
This phase II trial studies how well carboplatin and etoposide with or without oblimersen sodium works in treating patients with extensive stage small cell lung cancer.
- Trial name
- NCT00042978
- Testing
- oblimersen sodium, carboplatin, etoposide
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Small Cell Lung Cancer
Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy
This was a study to investigate the potential clinical benefit of trilaciclib (G1T28), a Cyclin Dependent Kinase (CDK) 4/6 inhibitor, in preserving the bone marrow and the immune system, in order to decrease chemotherapy-induced…
- Trial name
- NCT02514447
- Testing
- Trilaciclib, Topotecan
- Where
- 50 sites in United States, Belgium and 6 more
- Volunteers
- 123 people
- Sponsor
- G1 Therapeutics, Inc.
Small Cell Lung Cancer Extensive Stage
First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC
Monoclonal antibodies against programmed death 1 (PD-1) and its ligand PD-L1 have shown efficacy in patients with ES-SCLC in the monotherapy and combination therapy settings.
- Trial name
- NCT05745350
- Testing
- Pembrolizumab, Plinabulin plus Etoposide and Platinum
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Xiaorong Dong
Immunotherapy, Second-line Treatment
Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC
This study is a phase II clinical study of Cadonilimab (AK104) combined with or without chemotherapy in the treatment of PD-1 inhibitor-resistant extensive stage small cell lung cancer
- Trial name
- NCT05901584
- Testing
- Cadonilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Zunyi Medical University